


Addition of Nasal Mupirocin to Chlorhexidine Baths for Prevention of Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections

INTRODUCTION

- <u>The purpose of this research</u> is to determine if addition of nasal mupirocin to an existing CHG bathing protocol will decrease MRSA hospital-associated bloodstream infections.
- Patients in Intensive Care Units (ICUs) are at risk of acquiring Methicillin-resistant Staphylococcus aureus (MRSA) colonization, increasing the risk of a subsequent MRSA infection.
- Universal decolonization, with chlorhexidine (CHG) baths and nasal mupirocin, has the potential to reduce MRSA bloodstream infections.



DISCLOSURES

I have no actual or potential conflict of interest and no financial relationships to disclose in relation to this presentation

Rahn Snyder, BSN, RN, CIC, Kathleen Julian, MD

RESULTS

- \circ 1,239 patients had MRSA PCR collected on admission and nasal culture at \approx Day 15, Jan 2021 to Jun 2023 • 93 of the 1,239 patients were MRSA PCR-positive on admission
 - For these 93 MRSA positive patients, at Day 15 nasal culture:
 - 88% (of 93) were negative for MRSA
 - 12% (of 93) remained MRSA-positive •

- It also demonstrated that 88% of patients who were MRSA PCR positive on admission became MRSA-negative at Day 15 nasal culture.
- Automating the protocol is essential for operational consistency.

- Comparison: (p=0.049, by one tailed z-test)

DISCUSSION

- other hospital-associated infections.

REFERENCES

- 2. Huang, Susan S et al. "Targeted versus universal decolonization to prevent ICU infection." The New England journal of medicine vol. 368,24 (2013): 2255-65.
- Hospital Epidemiology. 2023;44(6):997-1001



• We measured how many MRSA-positive patients were successfully decolonized at Day 15:

To assess the clinical impact of adding nasal mupirocin to CHG baths, we measured ICU-attributable NHSN-qualifying MRSA bloodstream infections: (see FIGURE) • Pre-mupirocin period: 30 months before August 2020 (Feb 2018 - Jul 2020) Six MRSA bloodstream infections (0.16 cases per 1,000 ICU central-line days) • Post-mupirocin period: 30 months after August 2020 (Sep 2020 - Feb 2023) • One MRSA bloodstream infection (0.02 cases per 1,000 ICU central-line days) in study period after the addition of nasal mupirocin to daily CHG baths

Our research was modeled on an earlier universal decolonization study showing that nasal mupirocin/CHG bathing was associated with an overall reduction in ICU bloodstream infections and MRSA clinical isolates.² In our study, we assessed the contribution of adding five days of nasal mupirocin to a pre-existing CHG bathing protocol. At Day 15, 88% of MRSA-positive patients became MRSA-negative by nasal culture, demonstrating successful real-life protocol implementation among ICU patients. Most importantly, we observed a decrease in MRSA bloodstream infections.

Limitations include the use of historical controls. Complicating factors during the research period included the onset of the SARS-COV-2 pandemic—nationally there was an increase in MRSA BSIs. Future work is important to determine if decolonization of ICU patients will have sustained effects on MRSA bloodstream infections as well as

1. Centers for Disease Control and Prevention. (2024, February 5). Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line Associated Bloodstream Infection)

B. Lastinger LM, Alvarez CR, Kofman A, et al. Continued increases in the incidence of healthcare-associated infection (HAI) during the second year of the coronavirus disease 2019 (COVID-19) pandemic. Infection Control &